Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
View Patent ↗Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
1. A modified immune cell or precursor cell thereof, comprising a chimeric antigen receptor (CAR) that specifically binds MUC1, wherein the CAR comprises the amino acid sequence of SEQ ID NO:47.
2. The modified immune cell or precursor cell thereof of claim 1 , wherein the modified immune cell is a modified T cell.
3. An isolated nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO:46.
4. A chimeric antigen receptor (CAR) that specifically binds MUC1, comprising the amino acid sequence of SEQ ID NO:47.
5. An expression construct comprising the isolated nucleic acid sequence of claim 3 .
6. A method for generating the modified immune cell, comprising introducing into an immune cell the isolated nucleic acid sequence of claim 3 .
7. A method of treating a MUC1 associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective composition comprising the modified immune cell or precursor cell thereof of claim 1 .
8. The method of claim 7 , further comprising administering to the subject a lymphodepleting chemotherapy.
9. The method of claim 8 , wherein the lymphodepleting chemotherapy comprises administering to the subject a therapeutically effective amount of cyclophosphamide, and a therapeutically effective amount of fludarabine.
10. The method of claim 9 , further comprising administering to the subject a cytokine release syndrome (CRS) management regimen.